Back to top
more

Insulet (PODD)

(Real Time Quote from BATS)

$192.05 USD

192.05
298,830

-2.33 (-1.20%)

Updated Jul 25, 2024 09:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise

by Zacks Equity Research

Boston Scientific (BSX) registers a strong year-over-year improvement in sales, indicating solid market share gains in legacy businesses across all geographic regions.

Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View

by Zacks Equity Research

The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.

All You Need to Know About Insulet (PODD) Rating Upgrade to Strong Buy

by Zacks Equity Research

Insulet (PODD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.

ESLOY vs. PODD: Which Stock Is the Better Value Option?

by Zacks Equity Research

ESLOY vs. PODD: Which Stock Is the Better Value Option?

Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes

by Zacks Equity Research

Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.

Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System

by Zacks Equity Research

Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.

Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now?

by Zacks Equity Research

The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.

Here's Why Insulet (PODD) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Insulet (PODD) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised

by Zacks Equity Research

Insulet's (PODD) first-quarter performance benefits from the continued high demand for Omnipod 5.

Here's What Key Metrics Tell Us About Insulet (PODD) Q1 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Gear Up for Insulet (PODD) Q1 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Insulet (PODD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Insulet (PODD) Rises Higher Than Market: Key Facts

by Zacks Equity Research

In the most recent trading session, Insulet (PODD) closed at $173.42, indicating a +1.85% shift from the previous trading day.

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Insulet (PODD) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Insulet (PODD) reachead $166.19 at the closing of the latest trading day, reflecting a +1.23% change compared to its last close.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View

by Zacks Equity Research

Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.

Charles River (CRL) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.

Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised

by Zacks Equity Research

Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.

Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect

by Zacks Equity Research

Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.

Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?

by Zacks Equity Research

Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.

Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?

by Zacks Equity Research

STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.